Wegovy in the EU: how European approval differs from the UK picture

The misconception worth clearing up first: EU approval does not mean UK availability

A common reason people search "Wegovy EU" is a belief that because Wegovy is approved across Europe, it might be easier or cheaper to source from an EU country. That assumption runs into several hard walls. First, prescription medicines imported from abroad sit in a legal grey area for UK residents, the MHRA regulates what can be lawfully dispensed here, and a foreign pharmacy is not authorised to supply prescription medicines to UK patients. Second, an EU-registered product may differ in strength presentation, language labelling or storage documentation from the UK-licensed version. Third, and most practically: any seller willing to post prescription semaglutide across borders to you without a UK clinical assessment is operating outside the regulated supply chain, which is precisely where counterfeit and substandard products circulate.

The MHRA has been explicit on this point. Fake weight-loss pens have been seized in large quantities across the UK, some containing the wrong active substance entirely. Buying through a GPhC-registered pharmacy (one you can look up on the GPhC register) is the safe route, full stop.

What the UK licence for Wegovy actually covers in 2026

The UK's own regulatory picture for Wegovy has moved quickly, and it is worth knowing what is actually available here. The standard Wegovy injection (semaglutide 2.4 mg maintenance) has been licensed in the UK for weight management for several years. On 14 April 2026 the MHRA went a step further, approving a dedicated single-dose 7.2 mg Wegovy pen for adults with a BMI of 30 or above, a higher maintenance dose with a built-in covered needle that locks after use. Trial data for 7.2 mg reported around 20.7% average weight loss over 72 weeks, narrowing the gap with tirzepatide's results at the highest doses.

There is also a newer form to be aware of: oral semaglutide tablets (Wegovy tablets) were approved by the MHRA on 11 June 2026, making the UK the first country in Europe to licence an oral GLP-1 medicine for weight management. If you want to read more about how semaglutide works across its different formulations, that page covers the mechanism in detail. The EU has been following a similar regulatory trajectory, but if you would like a fuller picture of what Wegovy is and how it is used in the UK, that page brings together the key details in one place, and it makes clear why sourcing from abroad is even less logical.

NHS access versus private prescription in the UK

If you are wondering whether the EU regulatory picture affects NHS waiting times or eligibility, it does not. NHS access to Wegovy in England is governed by NICE technology appraisal TA875, which recommends semaglutide only within specialist weight management services, for a maximum of two years, for adults with a BMI of 35 or above (or 30 to 34.9 in certain clinical circumstances) and at least one weight-related condition. Waiting lists through those services are commonly long. Scotland, Wales and Northern Ireland operate under different criteria.

For people who do not meet NHS criteria or prefer not to wait, a private prescription through a GPhC-registered pharmacy is the alternative. You can read about what Wegovy costs privately in the UK if that context is useful, pricing has shifted since Novo Nordisk's supply position improved, and the page reflects current market reality honestly. Eligibility for a private prescription follows the licensed criteria: BMI 30 or above, or 27 or above with a weight-related condition such as hypertension, type 2 diabetes or high cholesterol. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. BMI alone never settles the question; a prescriber looks at the full clinical picture.

It is worth knowing that if you are already established on Wegovy, details like starting the 1 mg stage or moving to a higher maintenance dose are decisions made with your prescriber, not based on what another country's prescribing schedule looks like, and you can find guidance on the 0.5 mg starting dose if you are earlier in the titration journey. Our FAQ page covers common questions about ongoing treatment.

Semaglutide from EU sources: the safety case against it

If you have been quoted a lower price from a European online pharmacy, that is worth pausing on. Legitimate EU pharmacies are regulated by their national bodies and are not authorised to dispense to UK patients. Sellers who are willing to do so are, by definition, operating outside the framework designed to keep medicines safe. Counterfeit semaglutide pens have contained insulin, unknown substances and incorrect concentrations, none of which is visible to the naked eye.

The right question is not "can I get Wegovy from the EU" but "can I get genuine, clinically reviewed Wegovy quickly through a legitimate UK route". The answer to that is yes. The Wegovy 2 mg dose page sets out what that stage of treatment involves, and our weight loss treatment page covers all the options currently available. Our clinical team's profile is on the prescribers page if you want to understand who reviews consultations. For anyone ready to start, a free consultation is the first step, same-day clinical review by a GPhC-registered prescriber, no referral required.